Korean Post-marketing Surveillance for Onglyza®
Study identifier:CV181-171
ClinicalTrials.gov identifier:NCT01575483
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Korean Post-marketing Surveillance for Onglyza®
Medical condition
Diabetes Mellitus, Type 2
Phase
-
Healthy volunteers
No
Study drug
No Intervention (subjects were previously treated with Onglyza®)
Sex
All
Actual Enrollment
3433
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Mar 2012
Primary Completion Date: 07 Sept 2016
Study Completion Date: 07 Sept 2016
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Aug 2017 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients with T2DM Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled | Drug: No Intervention (subjects were previously treated with Onglyza®) No Intervention Other Name: saxagliptin |
Contacts
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
